https://sciex.com/content/SCIEX/na/us/en


Rapid Characterization of Biologics using CESI-MS

Jul 7, 2016 | Biopharma, Blogs | 0 comments

Today, 30 monoclonal antibodies (mAbs), have been approved for the treatment of certain cancers, autoimmune and infectious diseases. Even more are in development, and perhaps you and your team of scientists are working on one now.  Keeping pace with fast development timelines while performing comprehensive characterization of biologic candidates can be challenging. However, more and more, scientists are tackling these challenges with new techniques to speed and simplify their characterization workflows. Read more in the application note, “Rapid Characterization of Biologics using a CESI 8000 – SCIEX TripleTOF® System,” found in the Biologics Analytical Characterization Compendium, which highlights how CESI separation coupled with high-resolution mass spectrometry can provide a comprehensive characterization of biotherapeutics.

Download the Compendium to learn more >

Overview
Capillary electrophoresis (CE) integrated with electrospray ionization (ESI) creates a single dynamic process, called CESI. CESI coupled with the Information Dependent Acquisition (IDA) mode of a TripleTOF® 5600+ or 6600 systems can enable you to:

  • Use a single enzyme, single digestion protocol, followed by a single separation step to rapidly attain 100% primary sequence coverage for both the heavy and light chains of your mAb.
  • Identify important glycoforms, including those in low abundance.
  • Characterize amino acid modifications, including oxidation, deamidation, and lysine heterogeneity.

Make the shift to better biological characterization. Get to know the detailed analysis of experiments like this and much more including intact mass analysis, purity and heterogeneity determination, glycan analysis, biosimilar comparability, and host cell protein detection. With better information, you can make better decisions. Let the Biologics Characterization Compendium help guide you.

See the results in the full article, pages 56-65, by downloading the Biologics Analytical Characterization Compendium.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Supporting new CRISPR gene editing systems

Prime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high CRISPR/Cas9 editing efficiency and precision. However, the length requirement of pegRNAs at 120–250 nucleotides (nt) and their high level of secondary structure formation present analytical challenges for the purity analysis of chemically synthesized pegRNAs during development and quality control (QC).

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial